[Clinical Analysis of High-Dose Melphalan Combined with Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma].
High-dose melphalan in combination with ASCT as first-line consolidation therapy for MM can enhance the depth of patient response, further improve therapeutic efficacy, and the transplant-related complications are controllable, making it a viable option worth promoting in clinical practice.
Authors
- Dongping Huang (ORCID: https://orcid.org/0000-0003-3931-8385)
- Lan-Xin Zhang (ORCID: https://orcid.org/0000-0002-5918-8082)
- Lai-Quan Huang (ORCID: https://orcid.org/0000-0002-7139-9755)
- Guangxi Li (ORCID: https://orcid.org/0000-0002-2234-9188)
- Zhongling Wei (ORCID: https://orcid.org/0000-0002-2763-0964)
- Chen‐Li Cheng (ORCID: https://orcid.org/0000-0002-5785-2373)
- Chen Huang (ORCID: https://orcid.org/0000-0002-5707-7063)
Institutions
- Wannan Medical College (CN)
Publication Details
- Journal
- PubMed
- Published
- 2024-12-01
- DOI
- https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.06.018
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article